Saltar al contenido
Merck

Hepatocyte membrane potential regulates serum insulin and insulin sensitivity by altering hepatic GABA release.

Cell reports (2021-07-01)
Caroline E Geisler, Susma Ghimire, Chelsea Hepler, Kendra E Miller, Stephanie M Bruggink, Kyle P Kentch, Mark R Higgins, Christopher T Banek, Jun Yoshino, Samuel Klein, Benjamin J Renquist
RESUMEN

Hepatic lipid accumulation in obesity correlates with the severity of hyperinsulinemia and systemic insulin resistance. Obesity-induced hepatocellular lipid accumulation results in hepatocyte depolarization. We have established that hepatocyte depolarization depresses hepatic afferent vagal nerve firing, increases GABA release from liver slices, and causes hyperinsulinemia. Preventing hepatic GABA release or eliminating the ability of the liver to communicate to the hepatic vagal nerve ameliorates the hyperinsulinemia and insulin resistance associated with diet-induced obesity. In people with obesity, hepatic expression of GABA transporters is associated with glucose infusion and disposal rates during a hyperinsulinemic euglycemic clamp. Single-nucleotide polymorphisms in hepatic GABA re-uptake transporters are associated with an increased incidence of type 2 diabetes mellitus. Herein, we identify GABA as a neuro-hepatokine that is dysregulated in obesity and whose release can be manipulated to mute or exacerbate the glucoregulatory dysfunction common to obesity.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Ouabain octahydrate, ≥95% (HPLC), powder
Sigma-Aldrich
Betaine hydrochloride, ≥99%